Compare KKRT & BCTXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | KKRT | BCTXL |
|---|---|---|
| Founded | N/A | N/A |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | N/A |
| IPO Year | 2007 | 2025 |
| Metric | KKRT | BCTXL |
|---|---|---|
| Price | $20.83 | $0.80 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 68.8K | 16.0K |
| Earning Date | N/A | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 88.79 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $19,464,307,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $20.95 | $0.61 |
| 52 Week High | $25.93 | $1.40 |
| Indicator | KKRT | BCTXL |
|---|---|---|
| Relative Strength Index (RSI) | 26.19 | 44.15 |
| Support Level | N/A | $0.74 |
| Resistance Level | $23.35 | $1.16 |
| Average True Range (ATR) | 0.57 | 0.11 |
| MACD | -0.15 | -0.00 |
| Stochastic Oscillator | 0.88 | 33.06 |
BriaCell Therapeutics Corp is a clinical-stage biotechnology company developing targeted immunotherapies to transform cancer care. Its Bria-IMT targeted immunotherapy is being developed in combination with the immune checkpoint inhibitor Retifanlimab in a pivotal Phase 3 study in metastatic breast cancer. The Company's operations focus on the research and development of its immunotherapy product candidates and related supporting activities.